| [1] |
Fung-Kee-Fung SD.Therapeutic approaches in the management of locally advanced rectal cancer.J Gastrointest Oncol, 2014, 5(5): 353-361.
|
| [2] |
Glimelius B. Neo-adjuvant radiotherapy in rectal cancer.World J Gastroenterol, 2013, 19(46): 8489-8501.
|
| [3] |
Brenner H, Kloor M, Pox CP.Colorectal cancer.Lancet, 2014, 383(9927): 1490-1502.
|
| [4] |
Wang L, Li ZY, Li ZW, et al.Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.Dis Colon Rectum, 2015, 58(2): 186-192.
|
| [5] |
Petrelli F, Coinu A, Lonati V, et al.A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatnment and surgery for rectal cancer.Int J Colorectal Dis, 2015, 30(4): 447-457.
|
| [6] |
Fleshman JW, Smallwood N. Current concepts in rectal cancer.Clin Colon Rectal Surg, 2015, 28(1): 5-11.
|
| [7] |
Berho M, Narang R, Van Koughnett JA, et al.Modern multidiscliplinary perioperative management of rectal cancer.JAMA Surg, 2015, 150(3): 260-266.
|
| [8] |
Kerr SF, Norton S, Glynne JR.Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative moribidity without compromising prognosis.Br J Surg, 2008, 95(12): 1534-1540.
|
| [9] |
Tulchinsky H, Shmuell E, Figer A, et al.An interval > 7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer.Ann Surg Oncol, 2008, 15(10): 2661-2617.
|
| [10] |
Fernandez-Martos C, Nogue M, Cejas P, et al: The role of capecitabine in locally advanced rectal cancer treatment : An update.Drugs, 2012, 72: 1057-1073.
|
| [11] |
Hofheinz RD, Wenz F, Post S, et al.Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomized, multicentre, non-inferiority, phase 3 trial.Lancet Oncol, 2012, 13: 579-588.
|
| [12] |
Aschele C, Cionini L, Lonardi S, et al.Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized phase III trial.J Clin Oncol, 2011, 29: 2773-2780.
|
| [13] |
Gerard JP, Azria D, Gourgou-Bourgade S, et al.Comparison of two neoadjuvant chemoradiotherapy regeimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2.J Clin Oncol, 2010, 28: 1638-1644.
|
| [14] |
Connell MJ, Colangelo LH, Beart RW, et al.Capecitabine and oxalipatin in the preoperative multimodality treatment of rectal cancer: Surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.J Clin Oncol, 2014, 32: 1927-1934.
|
| [15] |
Dewdney A, Cunningham D, Tabernero J, et al.Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer(EXPERT-C). J Clin Oncol, 2012, 30: 1620-1627.
|
| [16] |
Nogue M, Salud A, Vicente P, et al.Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognossi locally advanced rectal cancer: The AVACROSS study.Oncologist, 2011, 16: 614-620.
|
| [17] |
Dipetrillo T, Pricolo V, Lagares-Garcia J, et al.Neoadjuvant bevacizumab, oxaliplatin, 5-fulorouracil, and radiation for rectal cancer.Int J Radiat Oncol Biol Phys, 2012, 82: 124-129.
|
| [18] |
Smith JJ, Garcia-Aquilar.Advances and Challenges in treatment of locally advanced rectal cancer.J Clin Oncol, 2015, 33(16): 1797-1808.
|
| [19] |
Lim SH, Chua W, Henderson C, et al.Predictive and prongnostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer.Crit Rev Oncol Hematal, 2015.
|